Endor Technologies, a biotechnology company based in the Barcelona Science Park (PCB-UB) and specialized in developing innovative solutions in dermocosmetics and oncology, has received an investment of €1.6 million from the Centre for the Development of Technology and Innovation (CDTI) to advance a pioneering treatment against liver metastasis. The Phase II clinical trial, designed by the company, will be carried out in collaboration with the Barcelona Clinical Coordinating Center (BCCC) of the Fundació Mon Clínic Barcelona and several leading hospitals across Spain. Endor’s most immediate goal is to achieve the First Patient In (FPI) in 2026, meaning the enrolment of the first patient in the trial.

The investment made by the CDTI endorses the soundness and scientific quality of the research line and makes it possible to fund the patient trial without interrupting investments in the company’s other two R&D lines, focused on dermocosmetics and healthcare solutions for oral mucositis. This is a pioneering clinical trial at a global level to test a therapy based on a principle entirely different from that of traditional oncology treatments.

For the first time, a strategy will be evaluated that does not aim to destroy tumors but to confine them, depriving them of space to grow and thereby inducing their natural necrosis. The initial phase will involve between 10 and 20 hospitals and plans to recruit around 100 patients in a clinical program lasting approximately two years.

“This support from the CDTI marks a turning point for Endor and acknowledges the effort of our scientific team,” says Joaquín Querol, CEO and co-founder of Endor Technologies. “We are exploring an unprecedented strategy based on a mechanism of action never before tested in humans. This breakthrough represents a decisive step toward continuing to transform research into applied science with a real impact on patients.”

The next steps include the validation of the clinical protocol for melanoma and colorectal cancer with liver metastasis by regulatory agencies, the selection of participating centers, the start of the regulatory process for the Phase II trial, as well as the recruitment of the first patients and the interim analysis of safety and efficacy.

The therapy under study is based on the administration of growth factors that stimulate the bone marrow to induce a structural response in the tumor microenvironment. The goal is to physically limit tumor expansion by confining it to a reduced space, thereby preventing its progression. This strategy contrasts with standard oncology treatments, which aim to destroy tumor cells through cytotoxicity, radiation, or immunotherapy.

» Link to the news: Endor Technologies website [+]